3 Health Services Stocks Moving The Industry Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 40 points (0.2%) at 17,108 as of Wednesday, Sept. 3, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,478 issues advancing vs. 1,497 declining with 182 unchanged.

The Health Services industry currently sits down 0.3% versus the S&P 500, which is up 0.1%. Top gainers within the industry include Catamaran ( CTRX), up 1.8%, Laboratory Corp of America Hldgs ( LH), up 1.6%, WellPoint ( WLP), up 1.1%, Aetna ( AET), up 1.0% and UnitedHealth Group ( UNH), up 1.0%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Abbott Laboratories ( ABT) is one of the companies pushing the Health Services industry higher today. As of noon trading, Abbott Laboratories is up $0.40 (0.9%) to $42.63 on light volume. Thus far, 1.7 million shares of Abbott Laboratories exchanged hands as compared to its average daily volume of 4.9 million shares. The stock has ranged in price between $42.35-$42.68 after having opened the day at $42.40 as compared to the previous trading day's close of $42.23.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Abbott Laboratories manufactures and sells health care products worldwide. Abbott Laboratories has a market cap of $63.5 billion and is part of the health care sector. Shares are up 10.2% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts who rate Abbott Laboratories a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Abbott Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Abbott Laboratories Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Covidien ( COV) is up $1.04 (1.2%) to $88.20 on light volume. Thus far, 957,267 shares of Covidien exchanged hands as compared to its average daily volume of 5.9 million shares. The stock has ranged in price between $87.27-$88.20 after having opened the day at $87.51 as compared to the previous trading day's close of $87.16.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $39.2 billion and is part of the health care sector. Shares are up 28.0% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts who rate Covidien a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, expanding profit margins and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Covidien Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Medtronic ( MDT) is up $0.62 (1.0%) to $64.53 on light volume. Thus far, 2.8 million shares of Medtronic exchanged hands as compared to its average daily volume of 9.0 million shares. The stock has ranged in price between $63.95-$64.53 after having opened the day at $64.00 as compared to the previous trading day's close of $63.91.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Medtronic, Inc. manufactures and sells device-based medical therapies worldwide. It operates through three segments: Cardiac and Vascular Group, Restorative Therapies Group, and Diabetes Group. Medtronic has a market cap of $63.6 billion and is part of the health care sector. Shares are up 11.4% year-to-date as of the close of trading on Tuesday. Currently there are 11 analysts who rate Medtronic a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Medtronic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Medtronic Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

Roku, Amazon, Teladoc, Weyerhaeuser: 'Mad Money' Lightning Round

Roku, Amazon, Teladoc, Weyerhaeuser: 'Mad Money' Lightning Round

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Cramer: 10 Points to Consider

Cramer: 10 Points to Consider

The 5 Best Dividend Aristocrats For 2018

The 5 Best Dividend Aristocrats For 2018

Lam Research: Cramer's Top Takeaways

Lam Research: Cramer's Top Takeaways